All In Biotech

Free tool

FAERS Monitor: Calquence

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216387 or its brand name (Calquence, Acalabrutinib Maleate). Reports on generic versions are filed under their own applications.

Reports

12,744

Serious

10,675

84% of reports

Hospitalization

3,481

Death reported

2,699

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death2,186
  • fatigue725
  • headache657
  • product dose omission issue522
  • diarrhoea443
  • fall395
  • dyspnoea352
  • contusion351
  • pneumonia337
  • malignant neoplasm progression325
  • asthenia314
  • pain302
  • off label use289
  • atrial fibrillation288
  • nausea283

Reports by year received

View as table
YearReports
20161
201744
2018193
2019198
2020588
20211,080
20221,443
20232,240
20242,719
20252,330
20261,908

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,415 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
contusionSignal3516.05.41,471
malignant neoplasm progressionSignal3255.34.71,116
atrial fibrillationSignal2884.94.4889
deathSignal2,1864.24.05,531
product dose omission issueSignal5222.92.7671
fall3952.01.8187
headache6571.71.6208
pneumonia3371.71.5102
fatigue7251.51.4141
asthenia3141.41.233
diarrhoea4431.11.07
dyspnoea3521.00.90
pain3020.80.713
nausea2830.60.583
off label use2890.50.5114

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.